HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial

Background Irinotecan is used as second-line treatment in advanced gastric or gastroesophageal junction (G/GEJ) cancer. The role of anti-programmed death-1 (PD-1) antibody plus irinotecan, in this setting and population is unclear.Methods This multicenter, open-label, single-arm, phase II trial was...

Cijeli opis

Bibliografski detalji

Glavni autori:	Ning Li, Shu Zhang, Yan Song, Jing Huang, Qun Li, Xinjun Liang, Qingxia Fan, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Xiaofei Wang, Yiwei Dou
Format:	Artigo
Jezik:	Inglês
Izdano:	BMJ Publishing Group 2020-10-01
Serija:	Journal for ImmunoTherapy of Cancer
Online pristup:	https://jitc.bmj.com/content/8/2/e001279.full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!